Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Kezar Life Sciences Inc (KZR)

Kezar Life Sciences Inc (KZR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Karora Announces Agreement with Kalamazoo Resources to Unlock Lithium Exploration Value Through Creation of Kali Metals Limited

/CNW/ - Karora Resources Inc. (TSX: KRR) ("Karora" or the "Corporation") is pleased to announce it has entered into an agreement with Kalamazoo Resources...

KZR.AX : 0.091 (unch)
KZR : 0.7900 (-1.42%)
KRR.TO : 5.44 (-0.55%)
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Kezar Life Sciences, Inc ., (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that...

KZR : 0.7900 (-1.42%)
Kezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business Update

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today reported financial...

KZR : 0.7900 (-1.42%)
Kezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the...

KZR : 0.7900 (-1.42%)
Kezar Life Sciences to Host Virtual R&D Day on March 22, 2023

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it will...

KZR : 0.7900 (-1.42%)
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Kezar Life Sciences, Inc ., (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that...

KZR : 0.7900 (-1.42%)
Kezar Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference

Kezar Life Sciences, Inc . (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Noreen...

KZR : 0.7900 (-1.42%)
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Kezar Life Sciences, Inc ., (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that...

KZR : 0.7900 (-1.42%)
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Kezar Life Sciences, Inc ., (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that...

KZR : 0.7900 (-1.42%)
Kezar Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

Kezar Life Sciences, Inc . (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that John...

KZR : 0.7900 (-1.42%)

Barchart Exclusives

This Dividend King Is Now One of BofA's Investment Best Ideas
Discover why S&P Global, a seasoned Dividend King, has not only secured a spot on Bank of America's prestigious US 1 List, but also why analysts are bullish about its investment potential in the current economic climate. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar